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Abstract
Background: Current therapies have succeeded in controlling AIDS pandemic. However, there is a continuing need
for new drugs, in particular those acting through new and as yet unexplored mechanisms of action to achieve
HIV infection cure. We took advantage of the unique feature of proviral genome to require both activation and
inhibition of splicing of viral transcripts to develop molecules capable of achieving long lasting effect on viral
replication in humanized mouse models through inhibition of Rev-mediated viral RNA biogenesis.
Results: Current HIV therapies reduce viral load during treatment but titers rebound after treatment is discontinued.
We devised a new drug that has a long lasting effect after viral load reduction. We demonstrate here that ABX464
compromises HIV replication of clinical isolates of different subtypes without selecting for drug resistance in PBMCs
or macrophages. ABX464 alone, also efficiently compromised viral proliferation in two humanized mouse models
infected with HIV that require a combination of 3TC, Raltegravir and Tenofovir (HAART) to achieve viral inhibition in
current protocols. Crucially, while viral load increased dramatically just one week after stopping HAART treatment,
only slight rebound was observed following treatment cessation with ABX464 and the magnitude of the rebound
was maintained below to that of HAART for two months after stopping the treatment. Using a system to visualize
single HIV RNA molecules in living cells, we show that ABX464 inhibits viral replication by preventing Rev-mediated
export of unspliced HIV-1 transcripts to the cytoplasm and by interacting with the Cap Binding Complex (CBC).
Deep sequencing of viral RNA from treated cells established that retained viral RNA is massively spliced but
importantly, normal cellular splicing is unaffected by the drug. Consistently ABX464 is non-toxic in humans and
therefore represents a promising complement to current HIV therapies.
Conclusions: ABX464 represents a novel class of anti-HIV molecules with unique properties. ABX464 has a long
lasting effect in humanized mice and neutralizes the expression of HIV-1 proviral genome of infected immune cells
including reservoirs and it is therefore a promising drug toward a functional cure of HIV.
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Background
AIDS is a worldwide pandemic. Current therapies have
succeeded in controlling the disease but long-term use
of Anti-Retroviral Therapy (ART), is limited by issues of
drug resistance and side effects [1-3]. Furthermore, the
current ART drugs need to be taken for life time and
only attenuate the disease without curing it [4]. Therefore,
there is a continuous need for new drugs to HIV cure, in
particular those acting through new and as yet unexplored
mechanisms of action [5].
We took advantage of the unique feature of the viral
genome once integrated in infected cells to require both
activation and inhibition of splicing of precursor mRNAs
to develop molecules capable of changing the balance
between spliced and unspliced products. The HIV-1 DNA
genome expresses a primary transcript of 9 kilobases (kb)
that not only serves as genomic RNA for progeny virus
but also as the mRNA that encodes the viral Gag and
Gag-Pol proteins [6-8]. Alternative splicing is a key event
for HIV replication. Successful infection and production
of new infectious viruses requires the balanced expression
of seven additional viral proteins (Rev, Tat, Nef, Vif, Vpr,
Vpu and Env) that are produced by splicing of the primary
9 kb transcripts among which the Tat and the Rev factors
are absolutely required for viral gene expression at the
transcriptional and post-transcriptional levels in infected
cells [9,10]. While most cellular unspliced RNAs are
retained in the nucleus where they are degraded, nuclear
export of the unspliced viral RNAs is facilitated by the Rev
protein, through binding to a viral sequence called the Rev
responsive element (RRE) [9,11,12].
After screening a collection of chemical compounds,
one indole derivative (IDC16) was discovered to interfere
with splicing enhancer activity of the SR protein splicing
factor SRSF1 [8,13,14]. This compound suppresses the
production of key viral proteins, thereby compromising
subsequent synthesis of full-length HIV-1 pre-mRNA and
assembly of infectious particles. However, IDC16 is a pla-
nar fused tetracyclic indole compound. Such molecules,
and in particular those in which the polyaromatic nucleus
is further substituted by a positively charged (protonated
aminoalkyl) side chain, have been studied as potential an-
ticancer agents [15,16]. The guiding principle is that they
intercalate DNA and exhibit cytotoxic effects by interfer-
ing with the function of DNA processing enzymes such as
topoisomerase I and II [17,18]. We thus designed alterna-
tive scaffolds which retain the structural characteristics of
IDC16 but which lose the inherent affinity of the flat poly-
cyclic molecules for DNA. We prepared molecules that
are more flexible as they have fewer fused rings. This
could circumvent potential side effects and allow a more
optimal interaction with the protein target. A dedicated li-
brary of 1,000 compounds of potentially more potent and
selective splicing modulators was synthesized.
Here, we describe ABX464, an enhancer of viral RNA
splicing with validated efficacy in humanized mouse
models of HIV-1 infection. ABX464 is the first therapeutic
molecule described to neutralize the expression of the
HIV-1 proviral genome and it is therefore a promising
drug towards HIV cure.
Results
Selection of ABX464
The first functional screening of the new compounds was
based on the use of freshly isolated human peripheral
blood mononuclear cells (PBMCs) from healthy donors.
These PBMCs were infected by the laboratory HIV strain
Ada-MR5. Every molecule was tested at 5 μM on at least 8
different blood isolates; for a rigorous selection of candi-
date molecules, we maintained the cells with or without
the drug for 6 days. Five compounds were selected follow-
ing these assays and they were demonstrated to have an
IC50 in the micromolar range. We selected one, ABX464
(Figure 1a) for further analysis. However, ABX464 is hydro-
phobic and forms aggregates when applied directly to cell
cultures, which leads to some toxicity to the cells (data not
shown). To avoid this problem, we prepared a soluble frac-
tion after adding the molecule to cell culture media and
elimination of aggregates by centrifugation (see Methods).
The binding of ABX464 to bovine serum albumin (BSA)
retains the molecule in the soluble fraction as determined
by mass spectrometry. Figure 1b, shows dose dependent
inhibition of HIV-1 replication by soluble ABX464 in
stimulated PBMCs from 5 different donors with an IC50
ranging between 0.1 μM and 0.5 μM. We also determined
the concentration of ABX464 with minimal side effects on
cell viability using an MTS test (Figure 1c) and cell prolifer-
ation was measured by the stable incorporation of the
intracellular fluorescent dye 5-(and −6)-carboxyfluores-
cein diacetate succinimidyl ester (CFSE) into lympho-
cytes (Figure 1d). ABX464 is only toxic at doses higher
than 60 μM but has no effect on cell proliferation.
To generalize the effect of ABX464 on HIV-1 replication
in other primary cells, the same protocol was repeated
using infected macrophages, which act as viral reservoirs.
Cells were treated with between 0.01 μM up to 30 μM
concentrations of ABX464 and p24 antigen levels were
monitored in culture supernatants over a 12 days period
(Figure 1e). Interestingly, ABX464 efficiently blocked virus
replication in a dose-dependent manner with an IC50 ran-
ging between 0.1 μM and 1 μM. However, cell viability was
not decreased under ABX464 treatment (data not shown).
ABX464 does not select for HIV specific mutations and it
is not genotoxic
To complement the previous experiments, which were
all performed with primary human cells infected with
macrophage-tropic (R5) strains (Ada-MR5 and YU2), we
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shifted to an in vitro system that may be more relevant
to the clinical situation. By infecting primary cells with
HIV-1 isolates from patients, we showed that ABX464 had
a strong inhibitory effect for all HIV-1 subtypes tested in-
cluding subtype B, C and recombinant viruses (Figure 2a).
A critical aspect of HIV infection is its ability to gener-
ate a diverse viral population through high replication
rates and high reverse transcriptase mutation rates.
Thus, in infected individual there is a broad pool of virus
that may survive in the face of pressure exerted from the
host as well as non-potent antiretroviral therapy. This
same mechanism is responsible for the selection of drug
resistance. ABX464 also very efficiently inhibited the repli-
cation of viral strains harbouring mutations that confer re-
sistance to different therapeutic agents in vitro (Figure 2b).
While the antiviral drug 3TC was not highly active on
K65R and M184V mutant strains, both strains were inhib-
ited by ABX464.
Genetic heterogeneity is a characteristic of HIV, which
contributes significantly to its ability to generate muta-
tions that overcome the efficacy of drug therapies. The
selection of drug resistant mutants in vitro can be read-
ily accomplished by maintaining the virus in a state of
sub-optimal growth, regulated by slowly increasing the
Figure 1 ABX464 Inhibits HIV-1 production in PBMC- and macrophages-infected cells. a Drawing of 10-chloro-2,6-dimethyl-2H-pyrido
[3′,4′:4,5]pyrrolo[2,3-g]isoquinoline (IDC16), 8-chloro-N-(4-(trifluoromethoxy)phenyl)quinolin-2-amine (ABX464) and 8-chloro-N-glucuronide-N-(4-
(trifluoromethoxy)phenyl)quinolin-2-amine) (ABX464-N-glucuronide) compounds. b HIV-1 strain Ada-MR5 was used to infect triplicate of activated
PBMCs from different donors (stimulated for two days with PHA and IL2) in the absence or presence of increasing concentrations of ABX464.
Supernatant was harvested 6 days post-infection (pi) and viral capsid protein p24 antigen was quantitated using a standard ELISA protocol. Each
point represents 5 donors. c Concurrently, cell viability was measured by MTS assay after 6 days of incubation and cytotoxicity was indicated as
percentage as compared with untreated cells. d Histogram plots of CFSE fluorescence of CD4+ (upper panel) or CD8+ (lower panel) after 3 days
culture without (blue and green curves, respectively) or with increasing concentrations of ABX464; 15 μM (red curves), 31 μM (yellow curves)
or 61 μM (pink curves). CD4+ and CD8+ T cells purified from PBMCs were labeled with CFSE and cultured with the indicated concentration of
ABX464 and then analysed by flow cytometry. The plots show the CFSE profiles of viable CFSE-labeled CD4+ and CD8+ T cells. e HIV-1 strain YU2
was used to infect triplicate of monocyte-derived macrophages from different donors in the absence or presence of increasing concentrations
of ABX464. Supernatant was harvested 8 days pi and viral capsid protein p24 antigen was quantitated using standard ELISA protocol. Each point
represents 9 donors.
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amount of drug pressure applied. Resistance to ABX464
was tested on human PBMCs and compared to current
therapies (Figure 2c). There were no resistance-inducing
mutations detected after treatment with ABX464 for at
least 24 weeks (Figure 2c).
We also applied a deep sequencing approach for sensi-
tive detection of low-frequency viral variants across the
entire HIV-1 genome. Viruses derived from treated and
untreated infected primary macrophages of 4 different
donors were sequenced and reads not aligning to human
genome were aligned to YU2 sequence using GSNAP
[19] (Raw data are provided upon request). The majority
of low and high frequency mutations were equally present
in treated and untreated samples, demonstrating that
ABX464 does not select for specific mutations (Additional
file 1: Figure S1a). To ascertain that amplification of viruses
from treated samples will not mutate when amplified in
PBMCs, they were sequenced following amplification with
or without drug pressure. Again, no novel mutations were
detected other than the ones existing before treatment in
the original samples (Additional file 1: Figure S1b). We
conclude that ABX464 was unlikely to select for specific
viral mutations that might inhibit viral replication.
The potential genotoxicity of ABX464 was also assessed
in GLP-compliant in vitro and in vivo studies and in nei-
ther case was ABX464 is genotoxic (see below, Additional
file 2: Table S1). This is making clear improvement to
fulfill criteria for clinical development, unlike IDC16.
ABX464 increases the levels of spliced HIV RNA
Since the parent drug IDC16 has a specific action on
HIV-1 pre-mRNA splicing, we assessed the efficiency of
ABX464 using the pΔPSP plasmid. pΔPSP containing
the HIV-1 proviral genome which is deleted between nu-
cleotides 1,511 and 4,550 (Additional file 3: Figure S2a)
and this plasmid recapitulates all splicing events of HIV-
1 pre-mRNA in transfected HeLa cells [13]. The mRNAs
produced by splicing were then analysed by RT-PCR
using forward and reverse primers that amplify several
differentially spliced isoforms encoding the viral proteins
Nef, Rev, and Tat. To assess whether ABX464 induced
preferential selection of a few splice sites and will favour
Figure 2 ABX464 inhibits different HIV-1 clades, resistant viruses and did not select for resistance. a Different HIV-1 strains (clade B, clade
C and recombinants clades) were used to infect PBMCs from three different donors in the absence or presence of 5 μM of ABX464. Supernatant
was harvested 6 days pi and viral capsid protein p24 antigen was quantitated using standard ELISA protocol. b RT activity (cpm) measured in
human PBMCs infected with different resistant mutants of NL4.3 strain (K103N, K65R and M184V) and treated with ABX464 or 3TC. c Resistance to
ABX464 was tested on human PBMCs and compared to current therapies (see Methods). There were no resistance-inducing mutations detected
after treatment with ABX464 for at least 24 weeks.
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the production of a specific viral RNA, amplified products
were visualized and analysed on the LabChip HT DNA
assay on an automated microfluidic station (Caliper,
Hopkinton, MA). Each band corresponding to specific
viral RNA was compared to total RNA amplified using
Caliper software. Unlike IDC16 which was previously
shown to completely block the production of spliced
viral RNA isoforms [13], ABX464 did not alter the splicing
profile when used at concentrations of 5 μM or 10 μM
(Additional file 3: Figure S2b). Besides, there was no sig-
nificant variation in the levels of each specific splice vari-
ants between treated and untreated samples (Additional
file 3: Figure S2c).
In order to verify that ABX464 did not significantly or
globally affect the splicing events of endogenous genes,
which could potentially lead to some adverse consequences,
the effect of ABX464 was tested by RT-PCR analysis on a
pre-existing panel of 382 alternative splicing events (ASEs).
These 382 ASEs represent a high-throughput (HT) random
snapshot of global alterations of alternative splicing. We
performed HT-PCR analysis of these (essentially random)
382 ASEs on multiple PBMC samples, with nine of our
drug derivatives, including ABX464, and with various con-
trols: either untreated or treated with DMSO or the con-
trol antiviral drug (Darunavir) [20,21]. Analysis of the data
allowed further stringent quality controls; ASEs were only
considered if >75% of the products ran at the expected
mobilities and if total expected PCR concentration was
higher than 20 nM. This filter ensured the use of high
quality PCRs on well-expressed genes and led to 264
remaining ASEs in our analysis. The splicing profiles of
the 12 PBMC samples are shown in Figure 3a compared
with stem cells and their derived fibroblasts (a previous
treatment that had previously been shown to result in
Figure 3 Effect of ABX464 on cellular and HIV-1 RNA splicing. a Heat map showing percent-spliced-in (psi) shifts for the 264 alternate
splicing events in positive control fibroblasts (fibroblasts) and their iPSCs (stem) untreated, PBMCs untreated (Cells) or PBMCs treated by either
DMSO without drug (DMSO) or with various compounds (ABX35, ABX36, ABX273, ABX388, ABX387 ABX402, ABX415, ABX449, ABX464 and Darunavir).
b Scatter plots comparing splicing changes for the 264 exons in PBMCs treated with ABX464 versus DMSO (left panel) or stem cells differentiated into
fibroblast (middle panel). The right panel shows a scatter plot comparing psi changes for the 264 exons induced by ABX464 to those induced
during stem cell differentiation. Pearson correlations (R values) are shown. c Visualisation of HIV-1 splice junctions after capture and sequencing
of HIV-1 RNAs extracted from PBMCs infected with the YU2 strain, either untreated (DMSO) or treated with ABX464 (ABX464) 3 days pi (d3) or
6 days pi (d6) using 454 pyrosequencing (according to GS junior method manual). Estimate of the distribution of read mappings, positions of
known acceptor (A1, A2, A3, A4a, A4c and A7) and donor splice sites (D1a, D2G4, D3 and D4), the exon-exon junctions (the line of accolade
which is dependent of the junction abundance) and the known coding regions of HIV-1, are shown.
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widespread splicing changes) [22]. This shows that there
was very little difference between the splicing profiles of
the drug-treated PBMC samples and controls, as they
formed one of three separate poles with the stem cells and
their derived fibroblasts. Consistent with this, the un-
treated cells and ABX464 treated cells per cent spliced in
values for these 264 ASEs had a high correlation of R =
0.89, whereas stem cells and derived fibroblasts correlated
poorly at R = 0.59 (Figure 3b). Taken together these data
show that ABX464 had a minimal or no global effect on
pre-mRNA splicing.
To test whether ABX464 influenced the splicing of
HIV RNA in infected cells, we performed an array-based
sequence capture using a customized library probes tar-
geting HIV sequences to get rid of cellular RNA. The
probes were used to capture cDNAs prepared from in-
fected treated and untreated PBMCs. After double cap-
ture, libraries were prepared and sequenced using 454
pyrosequencing (according to GS junior method manual).
The average size of the reads around 400 bp allowed un-
ambiguous assembly of viral genome from untreated sam-
ple (after 3 and 6 days of infection) using reads that were
not mapped to human genome (hg19) (Figure 3c). All se-
quencing data were analysed using GSNAP [19]. After
3 days post-infection we obtained 32,289 reads for the un-
treated DMSO sample and 4149 reads for ABX464 treated
sample. Strikingly, 17.4% of the reads from treated sample
corresponded to splice junctions, against 0.93% in the
untreated sample. While the number of reads from treated
and untreated samples were similar at 6 days post-
infection (20,585 and 27,984, respectively), the fraction
corresponding to splice junctions was again larger in
treated (13.3%) compared to untreated sample (1.93%).
Based on these results we conclude that ABX464 favoured
spliced HIV RNA in infected PBMCs, which compromised
subsequent synthesis of full-length HIV-1 pre-mRNA and
assembly of infectious particles (Figure 3c). Consistently,
standard procedures to measure unspliced and mutis-
pliced RNA by quantitative RT-qPCR, demonstrated that
ABX464 treatment produced 1.5 times more multispliced
RNA than unspliced RNA compared to untreated infected
cells (Additional file 3: Figure S2d).
In order to provide further evidence supporting the
hypothesis that the anti-HIV activity we observed with
ABX464 was the consequence of its inhibitory effect on
viral RNA splicing after proviral DNA integration, we
examined the effect of the drug on single round NL4.3R
E LUC virus containing the entire HIV-1 genome mutated
in the envelope gene and harbouring a luciferase marker
gene in the Nef position (Additional file 3: Figure S2e).
The amount of luciferase activity in cells infected with
these virions reflects both the number of integrated
proviruses and expression of multiply spliced species
encoding Nef/Luc. As expected luciferase activity was
strongly compromised with AZT treatment, as this drug
blocks the synthesis of proviral DNA. In contrast,
ABX464 treatment increased luciferase activity by more
than 2 fold compared to untreated infected cells. These
results confirmed that ABX464 acted after integration
and favours the production of multispliced RNA encod-
ing the luciferase protein.
ABX464 interacts with CBC complex and prevents Rev-
mediated export of unspliced viral RNA
To test the effect of ABX464 on splicing and/or export
of viral RNA, we used a state of the art system to visualize
single HIV RNA molecules in living cells. It is based on an
HIV reporter system containing the 5′ and 3′ LTRs that
harbour the promoter and polyA sites, respectively, pack-
aging sequences and RRE elements. In addition to this,
the construct contains 128 MS2 binding sites inserted
between the major donor HIV-1 site (SD1) and the last
splice acceptor (SA7) (Figure 4a). The reporter was intro-
duced in HeLa cells stably expressing Tat and MS2-GFP,
using the Flp-In system to create cells carrying a single
copy of the transgene. Stable expression of MS2-GFP pro-
tein allowed excellent visualisation of the transcription site
and single pre-mRNA molecules (Figure 4b) and did not
alter splicing rate (data not shown). To assay for RNA ex-
port, we transfected these cells with constructs expressing
Rev protein that will bind to the RRE and facilitate the
export of unspliced viral RNA, while protecting it from
the splicing machinery [23,24]. Rev expression led to a
reduced GFP signal at both the transcription site and in
the nucleoplasm (Figure 4b). This was expected since
following association of Rev with the high-affinity RRE
“nucleation site”, additional Rev molecules can polymerize
along the length of the RRE in a step-wise fashion through
both protein-protein and protein-RNA interactions [25],
thereby removing MS2-GFP from their target sequences.
Rev-mediated RNA export will also lead to a reduction of
unspliced RNA in the nucleus and a reduction in the inten-
sity of GFP in the nucleus. More nuclear GFP signal was
observed in Rev transfected cells treated with ABX464
compared to untreated cells (Figure 4 b and c upper panel).
Crucially, ABX464 interfered with both activities of Rev by
preserving the GFP signal both at the transcription site
(Figure 4 b and c lower left panel) and in the nucleoplasm
of cells expressing Rev (Figure 4 b and c lower right panel).
However, ABX464 showed no effect on reporter cells in
the absence of Rev (Additional file 4: Figure S3).
Both, RNA export and RNA splicing are controlled by
the cap binding complex (CBC) which interacts directly
with either Rev or the transcription/export (TREX) com-
plex, a multi-protein complex, required for transcription
and export of bulk mRNAs [26]. These interactions are
thought to recruit Rev and TREX to a region near the
5′-terminal cap structure of mRNA [27] and thereby
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connect the transcription and export of newly transcribed
RNAs. Since ABX464 interfered with Rev-mediated func-
tions, it was important to test whether ABX464 bounds to
either Rev or the CBC complex. Using a derivative of
ABX464 that has a photoactivatable moiety and competi-
tion with ABX464 on purified recombinant CBC20 and
CBC80 (CBC) [28], we discovered that ABX464, itself,
was able to induce dose-dependent covalent bridging be-
tween CBC20 and CBC80, after UV irradiation and this
complex could be resolved by SDS-PAGE (Figure 4d and
Additional file 5: Figure S4). Mass spectrometry analysis
of gel-purified CBC20, CBC80 and the putative complex
CBC (80 and 20), showed that the trypsin digestion of
CBC (80 and 20) complex gave rise to all predicted pep-
tides except the peptide corresponding to the position 37–
66 of CBC20 which was reproducibly under-represented
or absent (Additional file 6: Table S2). However, individual
digestion with trypsin of either CBC20 or CBC80 from
the same sample aroused all predicted peptides. Remark-
ably, the peptide 37–66 in the crystal structure of the
Figure 4 ABX464, influences REV-mediated HIV RNA biogenesis and export, and interacts with the CBC complex. a Schematic
representation of the HIV-1 reporter gene. b Visualization of GFP-MS2-Bound RNA in HeLa cells expressing Tat, MS2-GFP and HIV-reporter
transcripts in non-transfected or transfected cells with Rev. Rev-transfected cells were untreated (DMSO) or treated with ABX464 (ABX464). Arrow
indicates transcription site. c Quantification of images corresponding to untreated (DMSO) or treated (ABX464) in (b) of total GFP (upper panel), in
the nucleoplasm (left panel) or at the start site (right panel). Box-plots show the average GFP intensity (foci numbers or starting transcription point
numbers) of Rev-transfected HeLa cells for each condition. Whiskers correspond to the minimum and maximum, boxes, to the 25–75 percentiles
and the band inside the box, to the median. Statistical analysis was performed on at least 15 nuclei of Rev positive cells using an unpaired /t/-test
(**: p < 0.005 and ****: p < 0.0001). d Purified recombinant CBC20 and CBC80 proteins were incubated with increasing concentrations of ABX464
(left panel) or ABX464-N-glucuronide (right panel, Gluc) and treated for 30 minutes with UV light. The proteins were revealed by Western Blotting
using CBC20 and CBC80 antibodies. e Unlike m7GpppG cap structure, neither ABX464 nor ABX464-N-glucuronide interferes with the binding of
capped RNA to CBC complex. Recombinant human CBC was incubated with a capped RNA substrate and analysed by native gel electrophoresis
in order to resolve the different RNA and RNA-protein complexes: free RNA (lane 1), and CBC-RNA complexes (lanes 2–10) in the presence of 12 mM
of m7GppG (lanes 10) or 5 μM, 10 μM or 50 μM of ABX464 (lanes 2–4, respectively) or 5 μM, 10 μM, 50 μM or 100 μM of ABX464-N-glucuronide
(lanes 5–9, respectively).
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CBC [29] corresponded to the interface between CBC20
and CBC80, which could be the site of interaction
between ABX464 and the CBC [30] (Additional file 5:
Figure S4 a and b). The same results were obtained with
ABX464-N-glucuronide, a more soluble derivative of
ABX464 that is produced as unique metabolite using
human hepatocytes (see below).
However, neither ABX464 nor its metabolite ABX464-
N-glucuronide affected the binding of CBC complex
(Figure 4e) to capped RNA probe in a gel mobility shift
assay [31]. While the complex between CBC and capped
RNA was competed by the m7GpppG, no competition
was observed with ABX464 or ABX464-N-glucuronide at
any of the concentrations tested, confirming that ABX464
did not interact with the cap binding site of CBC20
(Figure 4e). Our results support the idea that ABX464
bound directly to CBC to specifically prevent Rev-
mediated export of viral RNA without interfering with
cap binding or export of cellular transcripts.
Efficacy of ABX464 in humanized mouse models
Humanized mice reconstituted with human lymphoid
cells provide rapid, reliable, reproducible experimental sys-
tems for testing the efficacy of ABX464 in vivo [32,33]. In
the initial setting, SCID mice were reconstituted with
PBMCs and then infected with the HIV-1 strain JR-CSF
[33,34]. Mice were treated twice a day (b.i.d) for 15 days
by oral gavage with 20 mg/kg of ABX464. Measures of
viral RNA showed that the oral treatment with ABX464
was able to significantly reduce the viral load over a period
of 15 days of treatment (Figure 5a). FACS analysis of blood
samples showed that treatment with ABX464 prevented
depletion of CD4+ cells following infection of reconsti-
tuted mice and thereby restored the CD8+/CD4+ ratio
back to that of non-infected mice (Figure 5b).
To test the long term effect of ABX464 on the im-
mune system and viral replication in infected humanized
mice (hu mouse), newborn NOG mice were transplanted
with CD34+ haematopoietic progenitor cells isolated from
the umbilical cord blood [35]. This hu mouse model has
previously been shown to be accurate for exploring the
antiviral potency of new compounds targeting the latent
HIV reservoirs [35]. Treatment of NOG hu mice for one
month with 20 mg/kg or 40 mg/kg of ABX464 neither al-
tered engraftment values of CD45+ cells nor the ratio of
CD8+/CD4+ compared to controls without treatment
(Figure 5c). In this study NOG hu mice were infected
with the YU2 HIV-1 virus and fed daily for 30 days with
40 mg/kg of ABX464 (Figure 5d left panel) or with
HAART (3TC-Tenofovir-Raltegravir) (Figure 5d middle
panel) and viral loads were measured as explicated be-
fore. Most significantly, unlike HAART, ABX464 leads
to a sustained reduction of viral levels in humanized
mice after treatment cessation (Figure 5d right panel).
Compared to HAART, ABX464 treatment induced a
slower kinetic of viral load reduction (Figure 5d left
panel). Whereas HAART was very efficient at reducing
the viral load to undetectable level after 2–3 weeks of
treatment in all infected mice (Figure 5d middle panel),
with ABX464 only 2 out of 6 mice had undetectable
levels of viral load, 2 mice were under 1000 copies and 2
mice are still have a viral load higher than 6000 copies
after 1 month of treatment (Figure 5d left panel). While
we cannot exclude the possibility that the slow kinetics
of viral reduction could be inherent to ABX464’s mode
of action, it is also possible that in this mouse model
ABX464 used as monotherapy, is inefficient at reducing
the viral load to undetectable levels. For instance mice
put on 3TC treatment alone for 42 days all had a viral
load above ABX464 (unpublished data). The most strik-
ing result is when the HAART treatment was stopped, 6
out 6 mice had a high viral load of above 17,000 RNA
copies, with some reaching 200,000 copies (Figure 5d
right panel). In contrast, only 2 mice out of 6 treated
with ABX464 demonstrated any rebound and that was
lower than the rebound after HAART (Figure 5d right
panel). Furthermore, these two mice had a viral load of
1,000 copies when we stopped the ABX464 treatment,
meaning that ABX464 had controlled most of the cells
contributing to viral rebound, at least during the 52 days
of treatment cessation. Moreover, 2 mice had undetectable
levels of viral load during the whole period of ABX464
cessation and two mice had low viral loads of under 1,000
copies (Figure 5d right panel). These results mean that
even though we can detect viruses in the blood, most in-
fected cells in the body that could contribute to viral re-
bound, mostly latently infected resting CD4+ T cells and
macrophages with integrated viral DNA [36,37], are not
producing new viruses after ABX464 treatment cessation.
ABX464 is readily metabolized and is non-toxic
Pharmacokinetic studies showed that ABX464 was rap-
idly absorbed, reaching a maximal plasma concentration
within a few hours of dosing in mice (Additional file 7:
Figure S5a). These results showed that the long lasting
effect in hu mice was due to a reduction of infected cells
and not due to a sustained accumulation of ABX464 in
the mouse. We tested the potential formation of ABX464
metabolites using cryopreserved hepatocyte primary cul-
tures from various species. The only ABX464 metabolite
detected upon incubation with human hepatocytes was
the ABX464-N-glucuronide (Figure 1a, Additional file 8:
Figure S6 a and b). This metabolite was also formed by
mouse and non-human primates, but not by rat, minipig
or dog hepatocytes (Additional file 8: Figure S6 a and b).
In the mouse at Tmax there was two times more ABX464-
N-glucuronide than ABX464 (Additional file 7: Figure
S5a). Interestingly, in vitro ABX464-N-glucuronide was as
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efficient as ABX464 in inhibiting replication of virus
strain YU2 in primary macrophages, without inducing
any toxicity (data not shown). Thus both ABX464 and
ABX464-N-glucuronide could be expected to induce in-
hibition of viral replication in humans. However, neither
glucuronide nor ABX464 were still detectable after 24 hours
post-treatment in mice (Additional file 7: Figure S5b right
panel). Moreover, cumulating dosing of ABX464 did not
sustain the presence of neither ABX464 nor ABX464-
N-glucuronide over 6 days after treatment cessation
(Additional file 7: Figure S5b left panel). Therefore, we
concluded that the long lasting effect, at least in mice,
cannot be attributed to glucuronide accumulation.
Furthermore, pharmacokinetic and toxicology studies
performed in non-human primates showed that ABX464
was rapidly absorbed with a maximal plasma concentra-
tion reached after 2 to 4 hours in marmoset monkeys
(Additional file 7: Figure S5c). ABX464-N-glucuronide
was formed rapidly with comparable Tmax values but
Cmax and AUC values were much higher for the metab-
olite than for the parent compound in non-human pri-
mates (Additional file 7: Figure S5c).
In rat, the no observed adverse effect level (NOAEL)
of ABX464 was achieved at a dose of 55 mg/kg b.i.d
(Additional file 2: Table S1). In non-human primates, the
main target organ of ABX464 toxicity was found to be the
Figure 5 Efficacy of ABX464 to inhibit viral replication in humanized mice. a Reconstituted SCID mice were infected with JRCSF HIV-1 strain
by intraperitoneal injection. The control group received labrafil and 5% DMSO by gavage (n = 15) and treated group 20 mg/kg b.i.d of ABX464 in
labrafil and 5% DMSO (n = 14) for 15 days. Two independent experiments were performed with 5 and 10 reconstituted mice for each group. Viral
load was assessed by measuring viral RNA using the Amplicor HIV-1 Monitor from Roche (limits of detection are delimited by interrupted lines).
b FACS analysis was performed on cells recovered by peritoneal wash at day 15 post-treatment to assess the CD8/CD4 ratio. c Engrafted NSG
humanized mice were treated by oral gavage with ABX464 at either 20 mg or 40 mg/kg once a day for 30 days and indicated lymphocyte
populations were monitored by FACS analysis. d NSG humanized mice were infected with the YU2 HIV-1 virus and treated either by oral gavage
with ABX464 at 40 mg/kg once a day for 30 days or by HAART (3TC-Tenofovir-Raltegravir) (grey boxes of left and middle panels). Right panel
represents viral loads after treatment cessation. For HAART, food pellets were made by mixing 2.5 g of 3TC and TDF each, and 5 g of RTV with
5 kg of ground protein-rich, vitamin-fortified food (Nafag 3432, Provimi Kliba AG, Switzerland) which was subsequently formed to food pellets
and sterilized by gamma-irradiation with 25 kGy. Viral load was assessed by measuring viral RNA using the Amplicor HIV-1 Monitor from Roche
(limits of detection are delimited by interrupted lines).
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gastro-intestinal tract. The NOAEL was considered to be
250 mg/kg b.i.d (Additional file 2: Table S1). Rough esti-
mate of the concentration in the animal indicate that these
NOEL dose are 50 times above the efficient dose required
to inhibit viral replication in vitro.
Discussion
In our attempt to identify new more potent and non toxic
HIV RNA splicing modulators inspired by the structure of
IDC16, we present ABX464 which we show targets Rev
function and therefore is susceptible to alter the viral ex-
pression in the reservoirs. The Rev protein facilitates the
transport of unspliced and singly-spliced RNA to the cyto-
plasm in infected host cells by binding to RRE and com-
peting with the major process of cellular mRNA export
[11,27,38]. This Rev’s essential role in HIV replication, its
mode of action and specific interactions with its target
RNA and cellular proteins enhance to the attractiveness
of Rev as a target. Despite the fact that, a variety of
approaches targeting Rev function, (including gene ther-
apy [39-41]) have been developed to inhibit HIV-1 repli-
cation in cells cultured in vitro [42-49], no therapies are
clinically available based on this mechanism. Many mol-
ecules selected this way have shown considerable tox-
icity in cells or have failed to specifically inhibit HIV
replication [42,43,45].
The finding that ABX464 binds to and stabilizes the
CBC complex (Figure 4 and Additional file 5: Figure S4),
together with the recent demonstration that Rev protein
specifies the viral RNA pathway by competing with TREX
complex [27], suggest that ABX464 acts as an agonist to
favour the normal pathway of export of spliced mRNAs.
Consistent with this suggestion, we found that ABX464
enhances the expression of spliced viral RNA, while redu-
cing the expression of unspliced RNA without having any
effect on cellular splicing (Figure 3).
Previous studies have shown that the presence of the
CBC complex on the 5′ RNA cap favours the recruit-
ment of TREX on the opened DNA at the transcription
site for efficient processing and export of the mRNP
[50,51], competition between Rev and TREX complex
may occur at the transcription site. Our data together
with recent observations using the MS2 system which
allows for visualization of events at the transcription site
and export [24], further confirm the hypothesis that Rev
and TREX compete with one another. The recruitment
of export factors to the site of transcription represents a
mechanism by which specific RNAs can be exported to
the cytoplasm by alternative mechanisms. If unspliced
viral RNAs are committed, to the CRM1 dependent ex-
port, by Rev [24], TREX-specific transport of multispliced
will be diminished [27,50,52]. Whether this competition
mechanism involves direct interaction between Rev and
CBC complex has been shown recently; Rev interacted
with the CBC80 subunit of the CBC complex and inhib-
ited the recruitment of the TREX complex [27]. ABX464
stabilizes the binding of CBC at the cap structure and thus
prevents Rev from seizing control of the TREX that binds
to the cap-proximal region and determines the RNA ex-
port pathway and splicing [50-52].
Current therapies specifically target individual viral en-
zymatic activities and this confers relatively little risk of
toxic effects to the host but the risk of developing resist-
ant viruses is high [53]. ABX464, on the other hand,
exploits a smaller windows of specificity by interfering
with Rev-mediated export pathway though direct binding
to the CBC complex. ABX464 is unlikely to induce the de-
velopment of resistance since it targets a cellular, rather
than a viral, component, (the CBC complex), ABX464 is
also expected be active on different HIV clades and mu-
tants viruses. Results presented here are consistent with
this expectation (Figure 2). ABX464 is globally not toxic
to infected cells because it has little effect on the export of
bulk mRNAs and did not alter splicing of cellular genes
nor the production of snRNAs nor of histones mRNAs
whose biogenesis are dependent on the CBC complex
[26]. By preventing Rev function, ABX464 restores the
normal pathway of global RNA biogenesis that is dis-
turbed by Rev expression in infected cells (with integrated
proviral genome). ABX464 outperforms known drugs that
target Rev in toxicological studies in all these ways and
could be used in combination with current treatments or
as a simpler and more effective replacement.
ABX464 reduces the viral load over a period of 30 days
of treatment (Figure 5d left panel) but more importantly,
the viral load remains low for at least 52 days after treat-
ment termination (Figure 5d right panel). In contrast,
rebound up to levels comparable to the initial infection
is seen in the HAART group (Figure 5d right panel).
ABX464 is thus the first anti-HIV drug able to suppress
viral load sustainably after treatment arrest. The long
lasting effect of ABX464 in mice could be explained by
the finding that ABX464 prevents HIV replication in
macrophages. The HIV-1 infected macrophages are of
critical importance in the pathogenesis of HIV because
macrophages have the ability to cross the blood-tissue
barrier and deliver the virus to all tissues and organs, in-
cluding the brain [37]. In addition, unlike T lymphocytes
that are depleted by viral infection, macrophages are
relatively less prone to the cytopathic effect of the virus
and infected macrophages harbour and produce the virus
for a longer period of time. Macrophages treated by
ABX464 are unable to produce viral particles to transmit
HIV-1 from macrophage to CD4+ T cells [36]. As macro-
phages act as the antigen presenting cells and present proc-
essed pathogen antigen peptides to the CD4+ T cells via
MHC II pathway [54], one would assume that viral pro-
teins produced from multispliced transcripts could serve as
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antigens to boost the immune anti-viral response. Given
that the expression of these multispliced viral RNA will de-
pend on the chromatin organization of the proviral DNA
in infected macrophages [55,56] and the cross talk between
chromatin and the splicing machinery [57-59], one would
speculate that ABX464 acting on the CBC complex at the
transcription site, might set up a chromatin structure fa-
voring the splicing of the primary transcript and that this
could thereby set up the long lasting effect of the drug.
Conclusions
In this report we present ABX464 first trials. Interestingly,
this drug presents a new mechanism of action for HIV
treatment and improves current therapies, hampering ap-
pearance of virus resistance. More importantly, it leads to
a long lasting control of the viral levels. We propose that
ABX464 could be used in combination with current drugs
or as a simpler and more effective replacement.
Methods
Ethics statement
All animal procedures were conducted in strict adher-
ence with the European Community Council Directive
of 24 November 1986 (86–609/EEC) and approved by
the cantonal veterinary office Zurich (#26/2011).
The procurement and use of CD34+ cells from human
cord blood was approved by the Cantonal Ethical Com-
mittee of Zurich (EK-1103). All adult subjects provided
written informed consent. Animal care and experimental
protocols were in accordance with the “Swiss Ethical
Principles and Guidelines for Experiments on Animals”,
and approved by the Veterinary office of the Canton of
Zurich, permit 26/2011. Manipulations of mice were in
accordance with the regulations of the Veterinary office
of the Canton of Zurich. (http://www.veta.zh.ch/internet/
gesundheitsdirektion/veta/de/home.html).
Drug dilution and handling
A 50 mM stock solution of each tested compound was
made in 100% DMSO and stored between −20°C and +4°C.
An intermediate solution at 500 μM was prepared in cell
culture medium (RPMI) complemented with 10% fetal
bovine serum. This solution was agitated for one hour
at 37°C on a Thermomixer at 1000 rotations per minute
and then stored over-night at +4°C. The following day,
the solution was subjected to centrifugation (16,000 rpm)
for 5 minutes and the supernatant was used to prepare the
various dilutions in cell culture media complemented with
10% fetal bovine serum, antibiotics (penicillin and strepto-
mycin) and IL-2 cytokine that were added to PBMCs.
Cell culture cytotoxicity evaluation and infection
Buffy coats from HIV-negative individuals were obtained
from the local blood donation center in Zurich, Switzerland
(http://www.blutspendezurich.ch/) and Centre de transfu-
sion sanguine Montpellier. Human peripheral blood mono-
nuclear cells (PBMCs) were isolated by Ficoll (Axis-Shield
PoC AS) gradient centrifugation. The cells were grown at
37°C, 5% CO2 to a density of 1.5×10
6 cells/ml in RPMI Glu-
tamax medium (Life Technologies) supplemented with 10%
fetal calf serum (FCS) (Thermo Fischer), 1,000 U/mL of IL2
(Peprotech) and 5 μg/mL of PHA (Roche) for activation.
Three days later, cells were pooled and resuspended to a
density of 1.5×106 cells/ml in RPMI Glutamax medium
supplemented with 10% fetal calf serum (FCS) and 1,000
U/ml of IL-2 for infection. HIV-1 infection has been per-
formed with 10 μg of Ada-M R5 HIV strain per ml of cells
for 4 hours. Cells were then centrifuged and resuspended
to a density of 1.5×106 cells/ml in medium supplemented
with diluted drug solubilized in DMSO (Sigma) according
to a final 0.05% DMSO concentration. Cells were treated
for 6 days with a partial medium change at day 3. From
cell culture supernatants, HIV p24 titration was performed
by ELISA with Ingen Innotest kit (Ingen) according to
manufacturer’s instructions.
To evaluate the cytoxicity of different compounds we
used the same protocol as above to seed the PBMCs in a
final volume of 100 μl without adding the virus. After
an incubation for 6 days at 37 C, a cell proliferation
assay has been performed. It is based on the conversion
of 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazo-
lyl)-3-(4-sulfophenyl)tetrazolium (MTS) to the coloured
product formazan in the presence of phenazine metho-
sulfate. The colorimetric conversion was proportional
to the number of viable cells in culture. The CellTiter
96® AQueous One Solution (Promega) has been added to
the assay wells (20 μl/well). Cells were incubated 4 hours
at 37°C and then absorbance is measured at 492 nm.
Mean and standard deviation of absorbance values for
triplicates were calculated. The cell viability percentage
of treated cells was determined by comparison between
treated cells absorbance value and untreated cells. The
cytotoxicity percentage was inversely deducted. Finally, the
TC50 was calculated by regression to determine the com-
pound concentration responsible for 50% of cytotoxicity.
To generate monocyte derived macrophages (MDMs),
monocytes were isolated using CD14 microbeads (Mil-
tenyi) and cultured in X-VIVO10 medium (Lonza)
supplemented with GM-CSF 1,000 U/ml and M-CSF
100 ng/ml for 6 days. Monocytes were seeded at a cell
count of 50,000 cells per well in a 96 well plate. After
6 days medium was replaced with X-VIVO10 w/o cyto-
kines. After 2 days macrophages were treated with
ABX464 or ABX464-N-Glucuronide o/n and next day
infected with Yu-2 virus for 6 hours, washed with PBS
and cultured in medium containing the compounds for
12 days. Supernatant for p24 ELISA was collected 2
times a week.
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HeLa cells from ATCC were cultivated at 37°C, 5%
CO2 in DMEM Glutamax medium (Life Technologies)
supplemented with 10% fetal calf serum (FCS) (Thermo
Fischer). pΔPSP (2 μg per 400,000 cells) transient trans-
fection was performed by JetPEI reagent (PolyPlus) ac-
cording to manufacturer’s instruction.
Jurkat CCR5 cells were cultivated at 37°C, 5% CO2 in
RPMI Glutamax medium (Life Technologies) supple-
mented with 10% fetal calf serum (FCS) (Thermo Fischer)
at 1.5×106 cells/ml. HIV-1 infection has been performed
with 30 ng of Ada-M R5 HIV strain per ml of cells for 4
hours. Cells were then centrifuged and resuspended to a
density of 1.5×106 cells/mL, plated in 6 multiwell plates (2
ml/well) supplemented with 2 ml diluted DMSO solubi-
lized drug (Sigma) according to a final 0.1% DMSO con-
centration. Cells were treated for 3 days. Total RNA was
extracted with the Machery-Nagel Nucleospin Triprep kit.
RNA was reverse transcribed utilizing a random hexamer
primer. Quantitative PCR (qPCR) analysis of the viral
transcripts was obtained with the following primer pairs
[RefSeq: M19921]: for all viral RNAs GGCCTGCTGT
AAGGGAAAG (8824–8842) and CTTGTGCCTGGCTA
GAAGC (8965–8947), for unspliced RNAs CTGAAGC
GCGCACGGCAA (706–723) and GAGATGGGTGCGA
GAGCGTC (806–787) and for multispliced RNAs GACT
CATCAAGTTTCTCTATCAAA (6018–6041) and ACC
ACCGCTTGAGAGACT (8534–8517). Each sample was
normalized by TATA box binding protein (TBP) [RefSeq:
NM003194] transcripts detected with the primers GT
TTCTTGGCGTGTGAAGATAACC (139–162) and GA
AACCCTTGCGCTGGAACTCGT (252–230). qPCR was
performed utilizing a Roche LightCycler real-time PCR
system and SYBR green dye, assays were carried out in
triplicate and analyzed with the LightCycler software.
U937 cells were grown at 37°C, 5% CO2 in RPMI Glu-
tamax medium (Life Technologies) supplemented with
10% fetal calf serum (FCS) (Thermo Fischer) at 1×106
cells/ml. Cells were pre-treated 48 hours with 10 μM of
molecule, then, single round infection has been per-
formed with 150 ng of P24 of a NL4.3 R−E−LUC-VSVg
production, per ml of cells in 6 multiwell plates (2 ml/
well) with or without ABX464 or AZT at 10 μM. Cells
were harvested at 24 hours and 48 hours post-infection,
wash once with PBS and one tenth of cells were lysed
with 200 μl of Passive Lysis Buffer (Promega). Protein
quantification was assessed by Bradford assay performed
by adding 200 μl of Bradford solution to 10 μl of cell lysate
(BioRad). After a brief incubation, the absorbance was
measured at 595 nm. Protein concentrations are estimated
by reporting to a BSA standard curve. In parallel, a lucifer-
ase assay (Promega) was performed by adding 70 μl of lu-
ciferin in 20 μl of cell lysate. Luminescence of each point
was measured and normalized by the protein concentra-
tion before being reported to the control.
HeLa 128*MS2-GFP cells (kind gift from E.Bertrand,
IGMM Montpellier, France) were maintained in DMEM
Glutamax medium (Life Technologies) containing 10%
fetal bovine serum (Hyclone), penicillin/streptomycin
(10 U/ml) in a humidified 5% CO2 incubator at 37°C.
Cells were transfected with pSG-FlagRev plasmid (kind
gift from P.Jalinot, ENS Lyon, France) for 24 hours with
JetPEI reagent (PolyPlus) according to manufacturer’s
instruction.
Selections for drug resistance and studies on resistant
viruses
Selections for resistance against various antiretroviral com-
pounds (ARVs) were performed as previously described
[60]. Briefly, HIV-1 infected cultures were grown in the
presence of the various ARVs tested beginning with drug
concentrations that were at or below the IC50 in each case,
including ABX464. Drug concentrations were gradually
increased and possible resistance-related mutations in
relevant regions of the HIV genome, such as the reverse
transcriptase open reading frame, were identified by se-
quencing. In the case of ABX464, it was not possible to in-
crease drug concentration above the IC50 because no
evidence of drug resistance was obtained.
Viruses of different subtypes or clades and viruses con-
taining the M184V and K65R resistance-associated muta-
tions in reverse transcriptase were generated as previously
described [61,62].
Immunofluorescence analysis
Cells plated on cover slips were fixed for 10 min in 3.7%
formaldehyde (in PBS) followed by a 2 min perme-
abilization with 0.1% Triton X-100 (in PBS) and incuba-
tion in PBS containing 0.1% bovine serum albumin. Rev
protein was revealed using antibody against HIV-1 Rev
protein (Santa Cruz) and nuclei were stained using
Hoechst 33342 (Sigma-Aldrich). Cells were washed in
PBS mounted with DAKO mounting medium and ob-
served under the fluorescence microscope.
Cell imaging was performed with a Leica DM6000
(Leica, Wetzlae, Germany) with PL APO grade oil × 63 ob-
jective. Images were captured with a Coolsnap HQ2 camera
(Roper Scientific Inc.) driven by Metamorph (Molecular
Devices) and processed using FiJi software and GFP
fluorenscence intensity was determined using the meas-
ure module of FiJi.
Image acquisition and image analysis were performed
on workstations of the Montpellier RIO Imaginig facility
of Plateau MRI CRBM Optique.
HIV RNA capture and sequencing
HIV RNA was captured on a NimbleGen SeqCap EZ
Developer Library following the manufacturer’s protocols
(Roche/NimbleGen). EZ Oligo pool was made against
Campos et al. Retrovirology  (2015) 12:30 Page 12 of 15
Ada-M R5 HIV strain. Total RNA was extracted from
PBMCs samples using TRIZOL reagent (Invitrogen) fol-
lowing the manufacturer’s protocol. The RNA concentra-
tions and purity were determined using the RNA 6000
Bioanalyzer kit (Agilent). For cDNA synthesis, 5 μg of
total RNA was treated with DNase I (Invitrogen) and then
utilized as a template for reverse transcription using the
Verso cDNA kit with a blend of random hexamers and
anchored oligo-dT (Thermo Scientific), according to the
manufacturer’s instructions. Libraries for sequencing were
prepared and sequenced using 454 pyrosequencing (ac-
cording to GS junior method manual).
Generation of humanized mouse models and infection
SCID mice were reconstituted with fresh human PBMCs
for two weeks and the reconstitution rates were estimated
by human IgG titration as previously described [32,33].
Reconstituted SCID mice were infected with JRCSF HIV-1
strain by intraperitoneal injection. Control group received
labrafil and 5% DMSO by gavage (n = 15) and the treated
group received 20 mg/kg b.i.d of ABX464 in labrafil and
5% DMSO (n = 14) for 15 days.
NOD.scid.IL2R −/− (NSG) mice were bred and main-
tained in individual ventilated cages and were fed auto-
claved food and water. Mice with a human immune system
(NSG-HIS) were generated as described [35]. Briefly, new-
born (<5 days old) NSG mice received sub-lethal (1Gy)
total body irradiation with a Cs source, and then received
2× 105 transduced or untransduced CD34+ human HSCs
using a 50 μl Hamilton syringe via the intrahepatic (i.h.)
route. Mice were infected intraperitoneally (i.p.) with HIV
YU-2, 1x106 TCID50 per mouse. All manipulations of
NSG-HIS mice were performed under laminar flow. Gav-
age of mice was performed daily with a stainless steel gav-
age needle (Straight 22 Gauge, 1,4inch in length). ABX464
was dissolved in DMSO (Sigma), and then diluted to 5%
or less according to the dose required in a suitable ve-
hicle (Labrafil; COOPER INDUSTRIE). Mice did not re-
ceive more than 150 μl in volume per day. Mice were
monitored three times a week for symptoms or signs of
adverse events, according to a standard score sheet.
HIV RNA plasma levels were measured by RT-PCR
(AmpliPrep/COBAS TaqMan HIV-1 Test, Roche) at
various times after infection.
HIV virus stock
Viral stocks were obtained by polyethylenimine (PEI)-
mediated transfection (Polysciences) of 293 T cells with
a pYU-2 (R5 tropic) plasmid provided through the NIH
AIDS Research and Reference Reagent Program. 48 hours
after transfection, the virus was harvested, filtered
(0.45 μm), and frozen at −80°C. Viral titers were deter-
mined as previously described [63]. Briefly, TCID50 (tis-
sue culture infectious dose 50%) was determined by
infecting human CD8+ T-cell-depleted peripheral blood
mononuclear cells (PBMCs) from three donors which
were stimulated by addition of IL-2, PHA and anti-CD3
beads (Life Technologies).
Flow cytometry
Cell suspensions were labeled with anti-human monoclo-
nal antibodies (mAb) targeting the following cell-surface
markers: CD45-FITC, CD3-PE, CD4-Pe Cy7, CD8-BV421
and CD19-APC (all from Biolegend). Washing and reagent
dilutions were done with FACS buffer (PBS containing 2%
fetal calf serum and 0.05% sodium azide (NaN3). All acqui-
sitions were performed on a Cyan ADP (Beckman Coulter)
flow cytometer. Data were analysed with FlowJo soft-
ware (Ashland, OR). Cellular debris and dead cells were
excluded by their light-scattering characteristics.
Additional files
Additional file 1: Figure S1. Sequencing of HIV-1 genome after
ABX464 treatment. a. HIV-1 strain YU2 was used to infect macrophages
from 4 different donors (D1, D2, D3 and D4) and viruses from the
supernatant of untreated (1–4) and treated (5–8) samples were harvested
8 days post-infection (pi) and subjected to deep sequencing using 454
pyrosequencing (according to GS junior method manual). Upper panel
schematic representation of different ORFs encoded by HIV-1 genome.
Position of all detected mutations/polymorphisms (POS). Corresponding
codons altered by the mutations at each position (CODON REF/ALT) and
expected amino acid changes (AA ref/Alt). Reference nucleotide (REF)
the corresponding mutated nucleotide (ALT) at each position. In blue are
the positions that were found to be mutated (the numbers indicate the
frequency of each mutation). In red are the positions that are unaffected.
b. Viruses from treated sample 5 in (a), was used to infect PBMCs from
donor D3 and D4 and viruses from the supernatant of untreated (9 and
10) and treated (11, 12) samples were harvested 6 days pi and subjected
to deep sequencing using 454 pyrosequencing (according to GS junior
method manual).
Additional file 2: Table S1. Tabular overview of toxicology studies.
Additional file 3: Figure S2. Effects of ABX464 on HIV RNA splicing
and viral DNA integration. a. schematic representation of HIV-1 genome.
b. ABX464 fails to inhibit splicing in HeLa cells transfected by p△PSP
plasmid. HeLa cells transfected with the p△PSP construct were either
untreated (DMSO) or treated with 5 μM or 10 μM of compound ABX464.
Multiply spliced products of HIV-1 RNA were amplified by RT-PCR according
to Bakkour et al. [13]. The PCR products were analyzed on a LabChip HT
DNA assay station (Caliper) for quantitation and sizing (according to
manufacturer’s instructions). Nomenclature of the RT-PCR products on
the right of the panel is according to Bakkour et al. [13]. c. The intensity
of each indicated band amplified in (b) was used to rigorously quantify
the changes in splicing products. Values are the average of three
independent experiments for untreated samples (DMSO) (white), treated
with 5 μM (grey) or 10 μM (black) and the level of expression is normalized
with that of total amplified signals. The value of untreated samples is equal
to 1. d. ABX464 enhanced expression of mutispliced viral RNA in infected
cells. The values of total RNA, unspliced and multispliced RNA in the
untreated sample are set to 100% (white) and the values of the same
RNAs in treated sample (grey) were compared to these values (left
panel). The ratio between multispliced and unspliced RNA in untreated
(white) and untreated sample (grey) are shown (right panel). e. ABX464
acts after integration of proviral DNA. U937 cells were pre-treated 48
hours with 10 μM of molecules of interest, then, single round infection
has been performed with NL4.3 R−E−LUC-VSVg with or without ABX464
or AZT at 10 μM as described in methods.
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Additional file 4: Figure S3. GFP expression of HeLa 128*MS2-GFP
cells expressing HIV reporter. Comparison between untreated (DMSO) or
ABX464 treated cells.
Additional file 5: Figure S4. ABX464 interaction with CBC complex. a.
Purified recombinant CBC20 and CBC80 proteins were incubated with
the indicated concentrations of ABX464-N-glucuronide and they were
either untreated (lanes 1–3), treated during 15 min (lanes 4–6) or 30 min
(lanes 7–9) with UV light. Proteins were analyzed by SDS-PAGE and
stained with Coumassie blue. ABX464 and ABX464-N-glucuronide
promotes UV crosslinking of CBC20 and CBC80. b. Recombinant human
CBC was incubated with ABX464-N-glucuronide and treated with UV for
15 min. After crosslinking the proteins were resolved in SDS-PAGE and
stained with Coomassie blue (left panel). Stained proteins (Band 4,
Band 5 and Band 7) were digested with trypsin and analysed by mass
spectrometry (details of mass spectrometry analysis of two independent
experiments are in Additional file 6: Table S2). Right panel shows the
Ribbon representation of the CBC complex (CBC20 in brown and CBC80
in purple) with the position of the cap RNA (in blue/red) on CBC20 and
the putative peptide of CBC20 that interacts with ABX464 (yellow).
Additional file 6: Table S2. Mass spectrometry analysis of CBC complex
and ABX464 interaction.
Additional file 7: Figure S5. ABX464 pharmacokinetics parameters. a.
Main plasma pharmacokinetic parameters of ABX464 and ABX464-N-
glucuronide in the mouse after an administration of 40 mg/kg of ABX464
by the oral route. b. Plasma pharmacokinetic parameters of ABX464 and
ABX464-N-glucuronide in the mouse after oral administration. Female
OF1 mice received 40 mg/kg of an ABX464 suspension in Labrafil - DMSO
5% per os, once a day during 28 days. Blood was sampled at day 0, 7, 14,
21 and 28 (left panel) or 0, 0.5, 2, 4, 6, 9 and 24 hours after gavage at day
0 (right panel) (5 animals per time point). After day 28 the gavage was
stopped in left panel (arrow shows end of the treatment). After 6 days of
stop of the treatment (left panel) or 24 hours post treatment (right panel),
neither ABX464 nor ABX464-N-glucuronide were still detectable. ABX464
and ABX464-N-glucuronide concentrations were quantified in plasma
by LC-MS. c. Plasma pharmacokinetic parameters of ABX464 in in the
marmoset monkey after one oral administration of 750 mg/kg of ABX464.
Additional file 8: Figure S6. ABX464 in vivo metabolism. a. In vitro
metabolism profiling of ABX464 in cryopreserved hepatocytes primary
cultures from various species. Hepatocytes were incubated with 10 μM
ABX464 for 120 minutes at 37°C. Aliquots from each supernatant culture
were analyzed by LC-MS/MS to identify potential ABX464 metabolites.
The number of peaks present in the chromatogram is indicated for each
metabolite in the corresponding species. b. Drawing and formula of
ABX464 metabolites.
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